GBLX News and Press, GB Sciences Inc From 03/15/22

LAS VEGAS, March 15, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to shareholders from President, Chief Science Officer, and Director Dr. Andrea Small-Howard and ...

Gb Sciences (OTCQB:GBLX) was issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Cardiac hypertrophy is the enlargement and thickening of the wal...

LAS VEGAS, March 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has been issued a new patent today by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture design...

LAS VEGAS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Following the promising study on cannabinoids and COVID-19 published by Oregon State University , Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-based biopharmaceutical research and development company, has advised that the truth behind...

LAS VEGAS, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. "Th...

LAS VEGAS, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gb Sciences , a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine release syndrome (CRS), one of the most dangerous complications of COVID-19. With report...

LAS VEGAS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company Gb Sciences has taken innovative steps to speed up the process and is developing key...

Gb Sciences (OTCQB:GBLX) has initiated new preclinical studies at the National Research Council of Canada (NRC) through its Canadian subsidiary GbS Global Biopharma. The NRC will test GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. Gb...

LAS VEGAS, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has initiated new preclinical studies at the National Research Council of Canada ("NRC") through GbS' Canadian subsi...

LAS VEGAS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB: GBLX) received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokin...